Cargando…

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report

Prolonged-release fampridine (PR-FAM), a potassium channel blocker, is approved for improving walking ability in patients with multiple sclerosis (MS). Beyond this, positive effects on other MS symptoms like fatigue, cognition, and tremor have been described. To our knowledge, a positive effect of P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Mona Klara Ros, Christ, Monika, Naumann, Markus, Bayas, Antonios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968993/ https://www.ncbi.nlm.nih.gov/pubmed/35371294 http://dx.doi.org/10.1177/17562864221083608

Ejemplares similares

Giant cell arteritis with vertebral artery involvement—baseline characteristics and follow-up of a monocentric patient cohort
por: Prünte, Mona Klara Ros, et al.
Publicado: (2023)

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
por: Hupperts, Raymond, et al.
Publicado: (2016)

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
por: Sola-Valls, Núria, et al.
Publicado: (2018)

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
por: Albrecht, Philipp, et al.
Publicado: (2018)

Autoimmune encephalitis associated with antibodies against the metabotropic glutamate receptor type 1: case report and review of the literature
por: Christ, Monika, et al.
Publicado: (2019)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination
por: Bayas, Antonios, et al.
Publicado: (2021)

Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases
por: Prugger, Michael, et al.
Publicado: (2013)

Incidence, clinical spectrum, and immunotherapy of non-ischemic cerebral enhancing lesions after endovascular therapy
por: Bayas, Antonios, et al.
Publicado: (2022)

Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function
por: Rabadi, Meheroz H., et al.
Publicado: (2013)

Prolonged-Release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: A Pilot, Double-Blind, Randomized, Placebo-Controlled Study
por: Jacques, François, et al.
Publicado: (2018)

Fampridine and quality of life in individuals with multiple sclerosis
por: Sagawa, Yoshimasa, et al.
Publicado: (2016)

Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
por: Castelnovo, Giovanni, et al.
Publicado: (2021)

A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study
por: Mitsikostas, Dimos D., et al.
Publicado: (2021)

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
por: Hupperts, Raymond, et al.
Publicado: (2022)

Large-scale cross-sectional online survey on patient-neurologist communication, burden of disease assessment and disease monitoring in people with multiple sclerosis
por: Christ, Monika, et al.
Publicado: (2023)

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
por: Hobart, Jeremy, et al.
Publicado: (2018)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study
por: Mamoei, Sepehr, et al.
Publicado: (2021)

Early cervical myelitis after human papilloma virus vaccination
por: Fernández-Fournier, Mireya, et al.
Publicado: (2014)

Early cervical myelitis after human papilloma virus vaccination
Publicado: (2015)

Early-onset Cervical Myelitis after COVID-19 Vaccination
por: Hayashi, Ryuichiro, et al.
Publicado: (2023)

Post‐Hypoxic Myoclonus after COVID‐19 Infection Recovery
por: Ros‐Castelló, Victoria, et al.
Publicado: (2020)

Cervical myelitis due to herpes zoster: case report
por: Tosunoğlu, Bünyamin, et al.
Publicado: (2023)

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis
por: Zeller, D, et al.
Publicado: (2014)

Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients
por: Moghadasi, Abdorreza Naser
Publicado: (2021)

Alemtuzumab-associated diffuse alveolar damage – a case report
por: Bayas, Antonios, et al.
Publicado: (2020)

Cervical Myelitis Mimicking Intractable Occipital Neuralgia
por: Kim, Ji-Sun, et al.
Publicado: (2014)

Isolated Propriospinal Myoclonus as a Presentation of Cervical Myelopathy
por: Marrero-González, Paula, et al.
Publicado: (2018)

Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Improvement of Isolated Myoclonus Phenotype in Myoclonus Dystonia after Pallidal Deep Brain Stimulation
por: Ramdhani, Ritesh A., et al.
Publicado: (2016)

A Case of Atopic Myelitis with Cervical Cavernous Angioma
por: Fukuda, Miyuki, et al.
Publicado: (2017)

Cervical Transverse Myelitis Following COVID-19 Vaccination
por: DOI, Kazuma, et al.
Publicado: (2022)

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
por: Keune, Philipp M., et al.
Publicado: (2015)

Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment
por: Ahdab, Rechdi, et al.
Publicado: (2019)

Tozinameran: Multiple sclerosis manifesting in the form of cervical myelitis: case report
Publicado: (2022)

Myelitis
por: Hay, Walter
Publicado: (1874)

Inspiratory Myoclonus
por: Dekker, Marieke C. J., et al.
Publicado: (2019)

Perampanel improved intractable myoclonus in two patients with myoclonus epilepsy
por: Iijima, Mutsumi, et al.
Publicado: (2019)

Eosinophilic Myelitis in the Cervical Cord Mimicking Intramedullary Cord Tumor
por: Park, Cheon Wook, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_n5lllunnsjjh0sbc6iq8pree5c